Description
| Description | Azelaprag is an effective small-molecule apelin receptor agonist. Azelaprag can be used to treat neurological diseases and cardiovascular diseases. |
| Targets&IC50 | RAGE:12.7 ± 7.6 nM (kd) |
| In vivo | In the transgenic Alzheimer’s disease animal model (tgAPPSwedish/London), azeliragon (5 mg/day) reduces Aβ plaque deposition, decreases overall Aβ burden while increasing Aβ levels in plasma, lowers sAPPβ and increases sAPPα levels, reduces inflammatory cytokines, slows cognitive decline, and improves cerebral blood flow.[1] |
| Synonyms | AMG 986 |
| Molecular Weight |
523.61 |
| Formula | C25H29N7O4S |
| CAS No. | 2049980-18-7 |
Storage
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Solubility Information
( < 1 mg/ml refers to the product slightly soluble or insoluble )
